Physician profile
Suzan Phillips
NPI 1669942926
$3,768.63
in general payments reported to CMS, 2019-2025
19 companies · $39.70 in 2025
The $39.70 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $712 · 2023: $1,394 · 2024: $1,082 · 2025: $39.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.77 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,428.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.64 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $386.70 | 2023-2024 | Stelara, Simponi, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $216.68 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.14 | 2021-2024 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $157.82 | 2021-2024 | Linzess |
| Celgene Corporation | $124.87 | 2021-2023 | Zeposia |
| Pfizer INC. | $98.03 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $97.76 | 2023-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $96.29 | 2022-2023 | Dupixent |
| Qol Medical, LLC | $74.29 | 2023-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $70.11 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $63.30 | 2023-2024 | Omvoh |
| Genzyme Corporation | $60.62 | 2024 | |
| Gilead Sciences, INC. | $53.77 | 2023-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $46.14 | 2021-2023 | Qsymia |
| Mylan Specialty L.P. | $41.81 | 2024 | Yupelri |
| Daiichi Sankyo INC. | $39.88 | 2023-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $15.64 | 2023 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzan Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.